endpoint Introduces PULSE? 3.0 Platform for IRT Systems in Clinical Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
endpoint Introduces PULSE? 3.0 Platform for IRT Systems in Clinical Trials


endpoint Introduces PULSE™ 3.0 Platform for IRT Systems in Clinical Trials

PR Newswire

SAN FRANCISCO, May 22, 2014 /PRNewswire/ --

PULSE enables highly customized IRT trial design while maintaining endpoint's signature 30-Day delivery timeline  

endpoint Clinical, Inc., a leading provider of Interactive Response Technology (IRT) systems via phone (IVRS), web (IWRS) and mobile (IMRS) for global clinical trials, today announced the launch of its next-generation PULSE 3.0 platform. The enhanced PULSE platform provides highly customized configuration and deployment of complex trial designs in a rapid and repeatable manner unmatched in the clinical trials industry.

Speaking from the company's San Francisco HQ, endpoint's CEO and co-founder Jonathan Dole cited the redesign of PULSE as a significant milestone in the company's development and growth:

"endpoint's PULSE revolutionized the IRT industry in 2010 by enabling drastic time-reduction for IRT system deployment, while providing highly customized trial designs. With the introduction of PULSE 3.0, endpoint's users have unprecedented access to a robust array of IRT trial design features and functionality through an intuitive interface, making endpoint's PULSE, the clinical trial industry's most robust configurable IRT solution."

The upgraded platform will be demonstrated at the annual Drug Information Association (DIA) conference on June 16 [ th   ]in San Diego, CA, where endpoint will have a booth (booth #2125). Clients can also learn more about PULSE 3.0 at (http://www.endpointclinical.com).

Note to editors  

About endpoint 

Headquartered in San Francisco, CA, endpoint Clinical is the premier provider of interactive response technologies (IRT) systems and solutions for the clinical trials industry. endpoint's proprietary IRT system configuration engine PULSE ™ provides non-technical users with the necessary tools to design and deploy customized IRT solutions to meet the unique needs of any given clinical trial for randomization services and supply chain management.

For media enquiries, or if you wish to find out more about PULSE 3.0 and other endpoint services, please contact:

Ciaran Donnelly, Marketing Consultant
Email: cdonnelly@endpointclinical.com
Phone: +44(0)777-2029-361
Website:  http://www.endpointclinical.com

SOURCE endpoint Clinical

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here